Karyopharm Therapeutics Investor Presentation — January 2022

Document content

1 ©2022 KARYOPHARM THERAPEUTICS INC.

January 2022A Commercial -Stage

Novel Cancer Therapies2 ©2022 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information

This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding Karyopharm’s

preliminary financial information forfourth quarter andfullyear 2021 ;guidance onitsexpected cash runway and2022 research anddevelopment expenses ;expectations toprovide annual revenue guidance

during Q12022 ;expectations andplans relating toXPOVIO oranyofitsdrug candidates, ifapproved, forthetreatment ofadult patients with relapsed orrefractory multiple myeloma orrelapsed orrefractory

diffuse large B-celllymphoma andother hematologic malignancies andsolid tumors ;commercialization ofXPOVIO oranyofitsdrug candidates, ifapproved, andthecommercial performance ofXPOVIO ;

submissions to,andthereview andpotential approval ofselinexor oranyofitsother drug candidates by,regulatory authorities, including theCompany’s regulatory strategy, theanticipated availability ofdata to

support such submissions, timing ofsuch submissions andactions byregulatory authorities andthepotential availability ofaccelerated approval pathways ;theexpected design oftheCompany’s clinical trials ;

andthetherapeutic potential ofandpotential clinical development plans forKaryopharm's drug candidates, especially selinexor andeltanexor .Such statements aresubject tonumerous important factors, risks

anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay cause actual events orresults todiffer materially from Karyopharm's current expectations .Forexample, there canbenoguarantee